The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aducanumab (1) binds to 3-7 amino acids of Aβ, targeting soluble oligomers and insoluble fibrils.418,419”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [418]
In the citing paper
“Aducanumab has been tested in a phase II study, demonstrating its biological effect in terms of Aβ removal via PET with amyloid tracer [56].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [56]
In the citing paper
“Additionally, amyloid was cleared from the six cortical regions of interest, namely the frontal, parietal, lateral temporal, sensorimotor, anterior, and posterior cingulate areas [43].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Studies have shown that amyloid deposition was reduced in all treatment groups at 26 weeks and further reduced by the end of the first year.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Anti-Aβ immunotherapies have shown reductions in amyloid PET and several amyloid reducing therapies for AD use amyloid PET (or CSF) as a key endpoint [172, 173].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [173]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 301–400 of 1,043
Small-molecule PET Tracers for Imaging Proteinopathies
Mathis, C. A., Lopresti, B. J., Ikonomovic, M. D., & Klunk, W. E. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.06.003 · Cited by 123
Questions EMERGE as Biogen claims aducanumab turnaround
Howard, R., & Liu, K. Y. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0295-9 · Cited by 123
Staging of Alzheimer's disease: past, present, and future perspectives
Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S., & Rosa-Neto, P. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.008 · Cited by 113
Kim, D., Kwon, H. J., & Hyeon, T. (2019) · Advanced Materials · doi:10.1002/adma.201807965 · Cited by 121
Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges
Pais, M. V., Martinez, L. D., Ribeiro, O. G., Loureiro, J. C., Fernandez, R., Valiengo, L. D. C. L., Canineu, P. R., Stella, F., Talib, L. L., Radanovic, M., et al. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0735 · Cited by 144
Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance
Vico Varela, E., Etter, G., & Williams, S. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.04.010 · Cited by 118
Leveraging preclinical models for the development of Alzheimer disease therapeutics
Scearce-Levie, K. A., Sanchez, P. E., & Lewcock, J. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0065-9 · Cited by 128
Lowe, S. L., Duggan Evans, C., Shcherbinin, S., Cheng, Y.-J., Willis, B. A., Gueorguieva, I., Lo, A. C., Fleisher, A. S., Dage, J. L., Ardayfio, P., et al. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.56 · Cited by 115
Protective actions of exercise-related FNDC5/irisin in memory and Alzheimer's disease
de Freitas, G. B., Lourenco, M. V., & De Felice, F. G. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15039 · Cited by 120
“…promotes neurogenesis, synaptogenesis, and mitochondrial biogenesis; and reduces the risk of neurological and neuropsychiatric disorders (Li et al., 2014; van Praag, Fleshner, Schwartz, & Mattson, 2014; Sigal et al., 2006; Viña, Sanchis-Gomar, Martinez-Bello, & Gomez-Cabrera, 2012).”
BackgroundZou, Y. F., Qian, Z., Chen, Y., Qian, H., Wei, G., & Zhang, Q. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00537 · Cited by 127
Jeon, S. G., Cha, M.-Y., Kim, J.-I., Hwang, T. W., Kim, K. A., Kim, T. H., Song, K. C., Kim, J.-J., & Moon, M. (2019) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2019.02.004 · Cited by 117
Artificial Intelligence and Machine Learning in Nuclear Medicine: Future Perspectives
Seifert, R., Weber, M., Kocakavuk, E., Rischpler, C., & Kersting, D. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.08.003 · Cited by 122
A practical approach to the management of cerebral amyloid angiopathy
Kozberg, M. G., Perosa, V., Gurol, M. E., & van Veluw, S. J. (2020) · International Journal of Stroke · doi:10.1177/1747493020974464 · Cited by 133
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
“These data reveal that antibodies that selectively bind to deposited Aβ, either because they bind aggregates with higher selectivity than monomer (Aduhelm [36], lecanemab [37], and gantenerumab [38, 39]) or bind modified forms of Aβ such as N3-pGAβ (donanemab[40–42]) highly enriched in deposited Aβ, can effectively lo…”
BackgroundAlzheimer’s disease CSF biomarkers: clinical indications and rational use
Niemantsverdriet, E., Valckx, S., Bjerke, M., & Engelborghs, S. (2017) · Acta Neurologica Belgica · doi:10.1007/s13760-017-0816-5 · Cited by 114
Progressive supranuclear palsy: Advances in diagnosis and management
Coughlin, D. G., & Litvan, I. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.04.014 · Cited by 110
Moreta, M. P.-G., Burgos-Alonso, N., Torrecilla, M., Marco-Contelles, J., & Bruzos-Cidón, C. (2021) · Biomedicines · doi:10.3390/biomedicines9111689 · Cited by 108
Predicting future rates of tau accumulation on PET
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Botha, H., Graff-Radford, J., Jones, D. T., Ferman, T. J., et al. (2020) · Brain · doi:10.1093/brain/awaa248 · Cited by 117
“Many of these trials have enrolled participants who have either preclinical or early Alzheimer’s disease (Sperling et al., 2014; Sevigny et al., 2016; Klein et al., 2019).”
BackgroundXie, J., Gonzalez-Carter, D., Tockary, T. A., Nakamura, N., Xue, Y., Nakakido, M., Akiba, H., Dirisala, A., Liu, X., Toh, K., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b09991 · Cited by 115
Lopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116
Fibrin drives thromboinflammation and neuropathology in COVID-19
Ryu, J. K., Yan, Z., Montano, M., Sozmen, E. G., Dixit, K., Suryawanshi, R. K., Matsui, Y., Helmy, E., Kaushal, P., Makanani, S. K., et al. (2024) · Nature · doi:10.1038/s41586-024-07873-4 · Cited by 116
Gao, L., Li, X., Meng, S., Ma, T., Wan, L., & Xu, S. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s235969 · Cited by 115
Amyloid-β oligomers in cellular models of Alzheimer’s disease
Fontana, I. C., Zimmer, A. R., Rocha, A. S., Gosmann, G., Souza, D. O., Lourenco, M. V., Ferreira, S. T., & Zimmer, E. R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15030 · Cited by 115
“Indeed, aducanumab, the most promising Aβ immunotherapy, first failed in the futility analysis for early mild cognitive impairment (MCI) or mild AD patients [a recent re-analyses of EMERGE clinical trial now suggests that aducanumab might be effective) (Abbasi, 2018; Sevigny et al., 2016).”
Green Tea Extracts EGCG and EGC Display Distinct Mechanisms in Disrupting Aβ42 Protofibril
Zhan, C., Chen, Y., Tang, Y., & Wei, G. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00277 · Cited by 115
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
Honig, L. S., Barakos, J., Dhadda, S., Kanekiyo, M., Reyderman, L., Irizarry, M., Kramer, L. D., Swanson, C. J., & Sabbagh, M. (2023) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12377 · Cited by 112
Alpha Synuclein: Neurodegeneration and Inflammation
Forloni, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065914 · Cited by 122
Sasmita, A. O., Depp, C., Nazarenko, T., Sun, T., Siems, S. B., Ong, E. C., Nkeh, Y. B., Böhler, C., Yu, X., Bues, B., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01730-3 · Cited by 125
“Notably, the 30% plaque reduction in OL-Bace1 cKO ;AD mice falls in the range of effect sizes achieved by aducanumab 24 and the FDA-approved lecanemab 25 antibody therapies.”
Precision pharmacology for Alzheimer’s disease
Hampel, H., Vergallo, A., Aguilar, L. F., Benda, N., Broich, K., Cuello, A. C., Cummings, J., Dubois, B., Federoff, H. J., Fiandaca, M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.014 · Cited by 108
Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer’s brain
Brinkmalm, G., Hong, W., Wang, Z., Liu, W., O’Malley, T. T., Sun, X., Frosch, M. P., Selkoe, D. J., Portelius, E., Zetterberg, H., et al. (2019) · Brain · doi:10.1093/brain/awz066 · Cited by 114
“Similarly, while recent results from anti-Aβ immunotherapy trials have been encouraging (Logovinsky et al., 2016; Satlin et al., 2016; Sevigny et al., 2016) it will be important to assess whether test antibodies can engage with toxic Aβ dimers.”
ResultSuper‐Resolution Infrared Imaging of Polymorphic Amyloid Aggregates Directly in Neurons
Klementieva, O. L., Sandt, C., Martinsson, I., Kansiz, M., Gouras, G. K., & Borondics, F. (2020) · Advanced Science · doi:10.1002/advs.201903004 · Cited by 123
Akel, H., Ismail, R., & Csóka, I. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.12.014 · Cited by 107
Kulenkampff, K., Perez, A.-M. W., Sormanni, P., Habchi, J., & Vendruscolo, M. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00254-9 · Cited by 116
Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers
Zucchi, E., Bonetto, V., Sorarù, G., Martinelli, I., Parchi, P., Liguori, R., & Mandrioli, J. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00406-3 · Cited by 107
Ayalon, G., Lee, S.-H., Adolfsson, O., Foo-Atkins, C., Atwal, J. K., Blendstrup, M., Booler, H., Bravo, J., Brendza, R., Brunstein, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2639 · Cited by 110
Immunotherapies for Neurodegenerative Diseases
Mortada, I., Farah, R., Nabha, S. M., Ojcius, D. M., Fares, Y., Almawi, W. Y., & Sadier, N. S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.654739 · Cited by 124
Brain energy metabolism: A roadmap for future research
Rae, C. D., Baur, J. A., Borges, K., Dienel, G. A., Díaz‐García, C. M., Douglass, S. R., Drew, K. L., Duarte, J. M. N., Durán, J., Kann, O., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16032 · Cited by 130
Lacosta, A.-M., Pascual-Lucas, M., Pesini, P., Casabona, D., Pérez-Grijalba, V., Marcos-Campos, I., Sarasa, L., Canudas, J., Badi, H., Monleón, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0340-8 · Cited by 111
“phase III clinical trial with an mAb targeting soluble Aβ species (solanezumab; Expedition3 trial) has shown an inability to significantly reduce amyloid cortical burden (although a favourable tendency was apparent) in patients with mild AD [56], whereas mAbs targeting fibrillary Aβ (aducanumab) have produced very pro…”
BackgroundImmunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice
Kastanenka, K. V., Bussiere, T., Shakerdge, N., Qian, F., Weinreb, P. H., Rhodes, K., & Bacskai, B. J. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2080-16.2016 · Cited by 110
Self-citationClinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy
Oxford, A. E., Stewart, E. S., & Rohn, T. T. (2020) · International Journal of Alzheimer's Disease · doi:10.1155/2020/5380346 · Cited by 107
“Finally, phase III studies of fibril tar- geting gantenerumab were stopped early for futility due to a lack of statistical significance between treatment (high dose: 225mg; low dose: 105mg) and placebo groups in measures of brain atrophy (as measured by volumetric MRI), CSF Aβ concentrations, cognitive decline (as mea…”
BackgroundMethodResultInfluentialAn, J., Kim, K., Lim, H. J., Kim, H. Y., Shin, J. W., Park, I., Cho, I., Kim, H. Y., Kim, S., McLean, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44818-x · Cited by 126
“Indeed, as various up-to-date AD treatment methods are emerging 12 – 14 , the importance of early disease diagnosis is being emphasized to considerwell-timedinterventionoftreatment,raisingthepossibilityof curing cognitive impairment 15,16 .”
BackgroundCaruso, G., Caraci, F., & Jolivet, R. B. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.004 · Cited by 110
“Preliminary positive results have been observed in prodromal AD patients with aducanumab, the first example of a monoclonal antibody developed by selecting human B-cell clones triggered by neo-epitopes present in soluble oligomers and insoluble fibrils (Sevigny et al., 2016).”
Grundman, M., Morgan, R., Lickliter, J. D., Schneider, L. S., DeKosky, S., Izzo, N. J., Guttendorf, R., Higgin, M., Pribyl, J., Mozzoni, K., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.11.001 · Cited by 96
for the REVERSE-SD Study Investigators, Prins, N. D., Harrison, J. E., Chu, H.-M., Blackburn, K., Alam, J. J., & Scheltens, P. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00843-2 · Cited by 107
“effects are limited to a dose of 10 mg/kg, where a moderately greater effect on amyloid plaque reduction is also seen [43].”
BackgroundBaruah, P., Moorthy, H., Ramesh, M., Padhi, D., & Govindaraju, T. (2023) · Chemical Science · doi:10.1039/d3sc02350h · Cited by 122
Disease modification and Neuroprotection in neurodegenerative disorders
Cummings, J. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0096-2 · Cited by 104
“Removal of plaques was associated with a beneficial impact on cognitive decline in studies of aducanumab, suggesting that fibrillar amyloid removal may correlate with DM in some therapeutic circumstances [33].”
BackgroundBateman, R. J., Cummings, J., Schobel, S., Salloway, S., Vellas, B., Boada, M., Black, S. E., Blennow, K., Fontoura, P., Klein, G., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01110-8 · Cited by 109
Self-citationMimicking Molecular Chaperones to Regulate Protein Folding
Ma, F., Li, C., Liu, Y., & Shi, L. (2019) · Advanced Materials · doi:10.1002/adma.201805945 · Cited by 116
Mullane, K., & Williams, M. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 105
Circular RNA Cwc27 contributes to Alzheimer’s disease pathogenesis by repressing Pur-α activity
Song, C., Zhang, Y., Huang, W., Shi, J., Huang, Q., Jiang, M., Qiu, Y. L., Wang, T., Chen, H., & Wang, H. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00865-1 · Cited by 112
Affinity Maturation Enhances Antibody Specificity but Compromises Conformational Stability
Shehata, L., Maurer, D. P., Wec, A. Z., Lilov, A., Champney, E., Sun, T., Archambault, K., Burnina, I., Lynaugh, H., Zhi, X., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.056 · Cited by 103
Antibody Therapy Targeting RAN Proteins Rescues C9 ALS/FTD Phenotypes in C9orf72 Mouse Model
Nguyen, L., Montrasio, F., Pattamatta, A., Tusi, S. K., Bardhi, O., Meyer, K. D., Hayes, L., Nakamura, K., Banez-Coronel, M., Coyne, A., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.11.007 · Cited by 105
Self-citationWalker, L. C. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3025 · Cited by 173
GSK3: A potential target and pending issues for treatment of Alzheimer's disease
Zhao, J., Wei, M., Guo, M., Wang, M., Niu, H., Xu, T., & Zhou, Y. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14818 · Cited by 297
Sleep apnea and the risk of dementia: a systematic review and meta-analysis
Guay‐Gagnon, M., Vat, S., Forget, M., Tremblay‐Gravel, M., Ducharme, S., Nguyen, Q. D., & Desmarais, P. (2022) · Journal of Sleep Research · doi:10.1111/jsr.13589 · Cited by 107
Zhu, K., Xiang, X., Filser, S., Marinković, P., Dorostkar, M. M., Crux, S., Neumann, U., Shimshek, D. R., Rammes, G., Haass, C., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.12.023 · Cited by 107
Jung, B.-K., Park, Y., Yoon, B., Bae, J.-S., Han, S.-W., Heo, J. E., Kim, D., & Ryu, K. (2023) · Autophagy · doi:10.1080/15548627.2023.2180202 · Cited by 114
“However, attempts to reduce insoluble protein aggregates in treating neurodegenerative diseases, including Alzheimer disease, have shown limited success [47,48].”
BackgroundPassive anti-amyloid β immunotherapy in Alzheimer's disease—opportunities and challenges
Heneka, M. T., Morgan, D., & Jessen, F. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01883-x · Cited by 123
Anti‐amyloid antibody treatments for Alzheimer's disease
Perneczky, R., Dom, G., Chan, A., Falkai, P., & Bassetti, C. (2024) · European Journal of Neurology · doi:10.1111/ene.16049 · Cited by 106
The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer’s Disease
Hillen, H. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01154 · Cited by 106
Iraji, A., Khoshneviszadeh, M., Firuzi, O., Khoshneviszadeh, M., & Edraki, N. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103649 · Cited by 111
Effects of neural stem cell transplantation in Alzheimer’s disease models
Hayashi, Y., Lin, H.-T., Lee, C.-C., & Tsai, K. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-0622-x · Cited by 118
“When transplanted intoTg2576 mice, dose-dependent reduction in both soluble and insoluble Aβ could be occurred and similar observations in a phase 1b randomized trial [75].”
ResultZeltins, A., West, J., Zabel, F., El Turabi, A., Balke, I., Haas, S., Maudrich, M., Storni, F., Engeroff, P., Jennings, G. T., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0030-8 · Cited by 104
“In terms of the so-called amyloid hypothesis, there is evidence that early dosing with antibodies specifically targeting N-terminal Aβ1–42 may be effective.(28) Clearly, frequent administration of antibodies over decades in patients without clinical symptoms would be impractical.”
Metal Binding of Alzheimer’s Amyloid-β and Its Effect on Peptide Self-Assembly
Abelein, A. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00370 · Cited by 109
Pathological mechanisms and treatment progression of Alzheimer’s disease
Zhang, J., Kong, G., Yang, J., Pang, L., & Li, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02886-9 · Cited by 303
“These biologics selectively bind and promote clearance of soluble Aβ oligomers and plaques, potentially slowing disease progression [177].”
Aducanumab for the treatment of Alzheimer’s disease: A systematic review
Rahman, A., Hossen, M. A., Chowdhury, M. F. I., Bari, S., Tamanna, N., Sultana, S. S., Haque, S. N., Al Masud, A., & Saif‐Ur‐Rahman, K. M. (2023) · Psychogeriatrics · doi:10.1111/psyg.12944 · Cited by 104
Can we learn lessons from the FDA's approval of aducanumab?
Liu, K. Y., & Howard, R. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00557-x · Cited by 104
Lacorte, E., Ancidoni, A., Zaccaria, V., Remoli, G., Tariciotti, L., Bellomo, G., Sciancalepore, F., Corbo, M., Lombardo, F. L., Bacigalupo, I., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220046 · Cited by 111
Cogswell, P. M., Andrews, T. J., Barakos, J. A., Barkhof, F., Bash, S., Benayoun, M. D., Chiang, G. C., Franceschi, A. M., Jack, C. R., Pillai, J. J., et al. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8469 · Cited by 93
Monte Carlo cross-validation for a study with binary outcome and limited sample size
Shan, G. (2022) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-022-02016-z · Cited by 116
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
“Aducanumab is a human monoclonal antibody selectively targeting different forms of aggregated Aβ, which, like gantenerumab, shows preferred binding to fibrils over protofibrils and has low affinity for Aβ monomers [61,82].”
BackgroundAn overview on recent in vivo biological application of cerium oxide nanoparticles
Inbaraj, B. S., & Chen, B. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.10.005 · Cited by 115
“[35] Sevigny J , Chiao P , Bussiere T , Weinreb PH , Williams L , Maier M , et al.”
BackgroundTaylor, X., Clark, I. M., Fitzgerald, G. J., Oluoch, H., Hole, J. T., DeMattos, R. B., Wang, Y., & Pan, F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00649-w · Cited by 94
“The enthusiasm for these immuno-therapies is often hindered by common and sometimes severe adverse events, amyloid-related imaging abnormalities (ARIA), observed in several clinical trials [3–5].”
BackgroundPlog, B. A., Mestre, H., Olveda, G. E., Sweeney, A. M., Kenney, H. M., Cove, A., Dholakia, K. Y., Tithof, J., Nevins, T. D., Lundgaard, I., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120922 · Cited by 101
“Tracer and antibody penetration were also quantified ex vivo in coronal sections, as described previously (1).”
InfluentialDNA repair in the trinucleotide repeat disorders
Jones, L., Houlden, H., & Tabrizi, S. J. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30350-7 · Cited by 106
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Hamano, N., Li, S.-D., Chougule, M., Shoyele, S. A., Gupta, U., Ajazuddin, et al. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1471058 · Cited by 101
“There are some drug molecules which selectively reduces the amyloid plaque formation like tarenflurbil [19], semagacestat (γ-secretase inhibitor) [20], solenezumab [21], and aducanumab (anti-Aβ antibody) [22] etc.”
BackgroundKarakatsani, M. E., Kugelman, T., Ji, R., Murillo, M., Wang, S., Niimi, Y., Small, S. A., Duff, K. E., & Konofagou, E. E. (2019) · Theranostics · doi:10.7150/thno.28717 · Cited by 98
“It was only until four years ago that the phase 1b clinical trial administering aducanumab in Aβ PET-positive patients (prodromal or mild AD) reported on reduced levels of Aβ in a dose- and time-depended regime, yet the trial was not valued for the clinical endpoints given the observational nature of the data and the…”
BackgroundMichalon, A., Hagenbuch, A., Huy, C., Varela, E., Combaluzier, B., Damy, T., Suhr, O. B., Saraiva, M. J., Höck, C., Nitsch, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23274-x · Cited by 109
Self-citationKrotee, P., Rodríguez, J. A., Sawaya, M. R., Cascio, D., Reyes, F. E., Shi, D., Hattne, J., Nannenga, B. L., Oskarsson, M. E., Philipp, S., et al. (2017) · eLife · doi:10.7554/elife.19273 · Cited by 105
“DOI: 10.7554/eLife.19273 15 of 26 promising strategy for therapeutic development, especially in light of the recent success of prelimi- nary studies with antibodies raised against amyloid-b (Sevigny et al., 2016).”
BackgroundInfluentialVidoni, E. D., Morris, J. K., Watts, A., Perry, M., Clutton, J., Van Sciver, A., Kamat, A. S., Mahnken, J., Hunt, S. L., Townley, R., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0244893 · Cited by 92
“However, the tracer can sufficiently track dose-related amyloid change in investigational medication trials [67], suggesting that if our failure to observe changes was related to measurement error, exercise is unlikely to have a large effect on cerebral amyloid levels.”
BackgroundAmyloid-Related Imaging Abnormalities: An Update
Roytman, M., Mashriqi, F., Al-Tawil, K., Schulz, P. E., Zaharchuk, G., Benzinger, T. L. S., & Franceschi, A. M. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.22.28461 · Cited by 99
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Treating Alzheimer's disease by targeting iron
Nikseresht, S., Bush, A. I., & Ayton, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14567 · Cited by 98
“Crenezumab (Cummings et al., 2018) and aducanumab (Sevigny et al., 2016) are two additional antibodies that have shown target engagement in early studies and are currently undergoing testing in larger clinical trials.”
BackgroundInterplay Between Mitochondrial Oxidative Disorders and Proteostasis in Alzheimer’s Disease
Llanos-González, E., Henares-Chavarino, Á. A., Pedrero-Prieto, C. M., García-Carpintero, S., Frontiñán-Rubio, J., Sancho-Bielsa, F. J., Alcain, F. J., Peinado, J. R., Rabanal-Ruíz, Y., & Durán-Prado, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01444 · Cited by 96
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 116
Early functional network alterations in asymptomatic elders at risk for Alzheimer’s disease
Nakamura, A., Cuesta, P., Kato, T., Arahata, Y., Iwata, K., Yamagishi, M., Kuratsubo, I., Kato, K., Bundo, M., Diers, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06876-8 · Cited by 109
Wang, X., & Zheng, W. (2019) · The FASEB Journal · doi:10.1096/fj.201801751r · Cited by 98
“influx and voltage-dependent Ca(2+) channel activity by betaamyloid-(1-40) in rat cortical synaptosomes and cultured cortical”
BackgroundLeinenga, G., Koh, W. K., & Götz, J. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00809-4 · Cited by 97
Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura
Banerjee, G., Adams, M. E., Jaunmuktane, Z., Lammie, G. A., Turner, B., Wani, M. A., Sawhney, I. M. S., Houlden, H., Mead, S., Brandner, S., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25407 · Cited by 106
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes
Gómez-Isla, T., & Frosch, M. P. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00642-9 · Cited by 96
Shrivastava, A. N., Aperia, A. C., Melki, R., & Triller, A. (2017) · Neuron · doi:10.1016/j.neuron.2017.05.026 · Cited by 98
Mo, J., Li, J., Yang, Z., Liu, Z., & Feng, J. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.469 · Cited by 90
“Sevigny et al.(37) found a slowing of clinical decline in MMSE score, when patients used aducanumab.”
BackgroundMethodInfluentialModulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer’s Disease
Toniolo, S., Sen, A., & Husain, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239318 · Cited by 94
“Although none have yet been granted a clinical license, on the basis of their effects on cognitive outcomes [73], there is good evidence that such therapies do reduce brain amyloid levels [74,75].”
BackgroundScholler, P., Névoltris, D., Bundel, D. D., Bossi, S., Moreno‐Delgado, D., Rovira, X., Møller, T. C., Moustaine, D. E., Mathieu, M., Blanc, É., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01489-1 · Cited by 104
Baghallab, I., Reyes-Ruiz, J. M., Abulnaja, K., Huwait, E., & Glabe, C. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180582 · Cited by 95
Park, S. H., Baik, K., Jeon, S., Chang, W. S., Ye, B. S., & Chang, J. W. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00269-8 · Cited by 95
Neuropathology of White Matter Lesions, Blood–Brain Barrier Dysfunction, and Dementia
Hainsworth, A. H., Minett, T., Andoh, J., Forster, G., Bhide, I., Barrick, T. R., Elderfield, K., Jeevahan, J., Markus, H. S., & Bridges, L. R. (2017) · Stroke · doi:10.1161/strokeaha.117.018101 · Cited by 95
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 93
Prevention of Alzheimer's Disease: Lessons Learned and Applied
Galvin, J. E. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14997 · Cited by 92
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94
“Aducanumab has been tested in a phase II study, demonstrating its biological effect in terms of Aβ removal via PET with amyloid tracer [56].”
MethodErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer’s disease
Wang, B.-J., Her, G. M., Hu, M.-K., Chen, Y.-W., Tung, Y.-T., Wu, P.-Y., Hsu, W.-M., Lee, H., Jin, L.-W., Hwang, S.-P. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618804114 · Cited by 91
“A recent report showcased results from a phase 1b trial of aducanumab immunotherapy demonstrating that patients with prodromal or mild AD exhibit a positive outcome in cognition assessments after being treated with aducanumab for 1 y (46).”
Background
Metadata
- Authors
- Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O’Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R. M., & Sandrock, A.
- Affiliations
- Biogen (United States) (US)
- Light Chain Bioscience (Switzerland) (CH)
- Butler Hospital (US)
- University of Zurich (CH)
- Corresponding author
- Sandrock, Alfred
- ORCID
- Venue
- Nature
- Published
- 2016-08-31
- Volume
- 537
- Issue
- 7618
- Pages
- 50-56
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2510806376
- Cited by
- 3,059
- References
- 42
- Citations by year
- 2026: 186 · 2025: 340 · 2024: 389 · 2023: 332 · 2022: 416 · 2021: 326 · 2020: 263 · 2019: 231 · 2018: 268 · 2017: 252 · 2016: 52
- FWCI
- 214.30
- Type
- journal article
- Language
- en
- Update notices
- addendum (2017-06-22)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- Biogen
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid plaques, anti-amyloid monoclonal antibodies, immunotherapy, amyloid hypothesis, transgenic mouse model, prodromal Alzheimer's disease, clinical deterioration, amyloid-related imaging abnormalities, drug safety and tolerability
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Animals, Brain, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Humans, Male, Mice, Transgenic, Middle Aged, Models, Biological, Solubility, Amyloid beta-Peptides, Clinical Trials, Phase III as Topic, Mice, Plaque, Amyloid, Antibodies, Monoclonal, Humanized, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.